Histologically or cytologically confirmed colorectal carcinoma
Patients must have received at least one oxaliplatin-contained chemotherapy before the study and did not want to receive or tolerate irinotecan- contained chemotherapy
Presence of at least one measurable disease which is defined as lesion that can be measured in at least 1 dimension as 20 mm with conventional CT or 10 mm with spiral CT scan
Serum bilirubin less than 1.5 times the upper limit of normal range (ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times the ULN if no demonstrable liver metastases or less than 5 times the ULN in the presence of liver metastases
Require to wait 28 days before entry onto the study after being treated with any immunotherapy, or biologic systemic (including any target therapy)
Written informed consent to participate in the trial
You may not be if
Presence of CNS metastasis
Other malignancy with the exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to the entry of study
Less than 4 weeks since previous treatment
Concomitant illness that might be aggregated by chemotherapy. For examples, active, non-controlled infection or other active, non-controlled disease such as congestive heart failure, angina pectoris, respiratory insufficiency, arrhythmia. It depends on investigation's decision.
Women of child-bearing potential without using a reliable and appropriate contraceptive method during study period
Pre existent sensory or motor neurotoxicity \> grade 2 according to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) (disabling paresthesia and/or significant motor loss)
Patients who are receiving other concomitant chemotherapy, radiotherapy or any other investigational therapy
Clareo Health | Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer
